诺和诺德(Novo Nordisk)新任首席执行官Maziar Mike Doustdar正式履新不到一个月。8月28日,其上任后的首次并购交易成功落地,聚焦于新型RNA技术领域。作为肥胖症治疗领域的先行者,诺和诺德在下一代药物的研发竞赛中逐渐面临挑战,如今该公司正寄望于新型RNA技术,以强化其早期研发管线。诺和诺德已与Replicate生物科学公司(Replicate Bioscience)签署...
Source Link诺和诺德(Novo Nordisk)新任首席执行官Maziar Mike Doustdar正式履新不到一个月。8月28日,其上任后的首次并购交易成功落地,聚焦于新型RNA技术领域。作为肥胖症治疗领域的先行者,诺和诺德在下一代药物的研发竞赛中逐渐面临挑战,如今该公司正寄望于新型RNA技术,以强化其早期研发管线。诺和诺德已与Replicate生物科学公司(Replicate Bioscience)签署...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.